Key facts
- This page summarizes Robert Doebele's Form 4 filing for Rain Therapeutics Inc..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 04 Apr 2022, 16:15.
Robert Doebele - 31 Mar 2022 Form 4 Insider Report for Rain Therapeutics Inc.
- Reporting relationship
- President, Chief Scientific Officer
- Issuer ticker
- N/A
- Reported as of
- 31 Mar 2022
- Net transaction value
- +$7,900
- SEC form
- 4
- Accepted by SEC
- 04 Apr 2022, 16:15:31 UTC
- Prior SEC filing
- 04 Feb 2022
- Next SEC filing
- 15 Apr 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Nelson Cabatuan, Attorney-in-fact for Robert Doebele
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert Doebele filed Form 4 for Rain Therapeutics Inc. on 04 Apr 2022.
Change
- Previous filing in this sequence was filed on 04 Feb 2022.
- Current net transaction value: +$7,900.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RAIN
transaction
Common Stock
Options Exercise
- Transaction value
- $7,900
- Shares
- +2,000
- Change %
- +0.43%
- Price
- $3.95
- Shares after
- 469,937
- Date
- 31 Mar 2022
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RAIN
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -2,000
- Change %
- -14%
- Price
- $0.000000
- Shares after
- 11,890
- Date
- 31 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,000
- Exercise price
- $3.95
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
This option represents a right to purchase a total of 13,890 shares of Issuer's common stock, which is vested in full.
SEC remarks
President, Chief Scientific Officer